KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Account Payables (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Change in Account Payables data on record, last reported at $38.3 million in Q4 2025.

  • For Q4 2025, Change in Account Payables rose 355.95% year-over-year to $38.3 million; the TTM value through Dec 2025 reached $36.8 million, down 25.66%, while the annual FY2025 figure was $36.8 million, 25.66% down from the prior year.
  • Change in Account Payables reached $38.3 million in Q4 2025 per VRTX's latest filing, up from -$35.3 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $159.9 million in Q4 2022 and bottomed at -$69.9 million in Q3 2022.
  • Average Change in Account Payables over 5 years is $14.4 million, with a median of $8.0 million recorded in 2024.
  • Peak YoY movement for Change in Account Payables: tumbled 3425.24% in 2021, then soared 26100.0% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $53.9 million in 2021, then soared by 196.66% to $159.9 million in 2022, then tumbled by 119.89% to -$31.8 million in 2023, then surged by 126.42% to $8.4 million in 2024, then skyrocketed by 355.95% to $38.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $38.3 million in Q4 2025, -$35.3 million in Q3 2025, and $7.6 million in Q2 2025.